About Elastrin Therapeutics
Elastrin Therapeutics is a private company based in Greenville, South Carolina. It has reported $13,348,000 raised in five offerings on Form D since March 2021.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Sep 12, 2024amended Mar 11, 2025 | $500,000fully sold | 1 | $500K | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 25, 2023 | Nov 3, 2023 | $4,750,000fully sold | 3 | $1.5M | EquityRule 506(b) | Form D ↗ |
| Aug 11, 2023 | Sep 8, 2023amended Nov 3, 2023 | $2,000,000fully sold | 2 | $1.0M | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Mar 23, 2022 | Mar 25, 2022 | $3,598,000of $10.0M target | 3 | $1.1M | EquityRule 506(b) | Form D ↗ |
| Feb 17, 2021 | Mar 1, 2021amended Mar 25, 2022 | $2,500,000fully sold | 1 | $2.5M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, five offerings | $13,348,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Elastrin Therapeutics's Form D filed Mar 11, 2025.
NV
Naren Vyavahare
Executive officer and director
Earlier filings also listed Patrick Burgermeister (director, last listed Nov 2023), Matthias Breugelmans (executive officer and director, last listed Nov 2023) and Klaus-Dieter Langner (director, last listed Nov 2023).